Participación del sistema endocanabinoide
en el desarrollo de obesidad
Author
dc.contributor.author
Valenzuela, Carina
Author
dc.contributor.author
Aguirre, Carolina
Author
dc.contributor.author
Castillo, Valeska
Author
dc.contributor.author
Ronco Macchiavello, Ana María
Author
dc.contributor.author
Llanos Silva, Miguel
Admission date
dc.date.accessioned
2019-03-11T13:00:06Z
Available date
dc.date.available
2019-03-11T13:00:06Z
Publication date
dc.date.issued
2010
Cita de ítem
dc.identifier.citation
Rev Med Chile 2010; 138: 621-629
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165033
Abstract
dc.description.abstract
Endocannabinoids are the endogenous ligands for the cannabinoid receptors type
1 and 2. These membrane receptors are responsible for the psychotropic effects of
Cannabis Sativa, when bound to its active component known as (-)-D9-tetrahydrocannabinol.
Cannabinoid receptors, endocannabinoids and the enzymes catalyzing
their biosynthesis and degradation, constitute the endocannabinoid system (ECS),
which has a remarkable role controlling energy balance, both at central nervous system
and peripheral tissues. The ECS regulates food ingestion by stimulating a network
of orexigenic neurons present in the hypothalamus and reinforcing motivation and
reward to food consumption in the nucleus accumbens. Regarding peripheral tissues,
this system controls lipid and glucose metabolism at different levels, reduces energy
expenditure and leads energy balance to fat storage. Metabolic alterations, including
excessive accumulation of abdominal fat, dyslipidaemia and hyperglicaemia,
are suggested to be associated to a hyperactivated ECS. Since obesity is one of the
major health problems in modern societies, in this review we discuss the role of the
endocannabinoid system in metabolic pathways associated to control mechanisms of
energy balance and its involvement in overweight and obesity. In addition, we also
discuss therapeutic possibilities and emergent problems due to cannabinoid receptor
type 1 antagonism utilized as treatment for such alterations.